Role of Chemotherapeutic Agents in the Management of Cystic Echinococcosis

Nazligul Y., Kucukazman M., Akbulut S.

INTERNATIONAL SURGERY, cilt.100, ss.112-114, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 100
  • Basım Tarihi: 2015
  • Doi Numarası: 10.9738/intsurg-d-14-00068.1
  • Dergi Adı: INTERNATIONAL SURGERY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.112-114
  • Anahtar Kelimeler: Cystic echinococcosis, Drug treatment, Albendazole, Mebendazole, Praziquantel, HYDATID CYST, ALVEOLAR ECHINOCOCCOSIS, SINGLE-CENTER, PRAZIQUANTEL, DISEASE, BENZIMIDAZOLES, ALBENDAZOLE, EXPERIENCE, GRANULOSUS, LIVER
  • İnönü Üniversitesi Adresli: Evet

Özet

Hydatid disease is caused by infection with the metacestode stage of Echinococcus tapeworms of the family Taeniidae. The primary carriers are dogs and wolves, and humans are accidental hosts that do not contribute to the normal life cycle of this organism. The liver is the most commonly involved organ in the body by cystic echinococcosis (CE) secondary to infection with Echinococcus granulosus. Management options for CE should depend on the World Health Organization (WHO) diagnostic classification. Small (<5 cm) WHO stage CE1 and CE3a cysts may be primarily treated with benzimidazoles; the first-choice drug is albendazole. In some situations the combination of albendazole and praziquantel may be preferred. Chemotherapy with a benzimidazole or albendazole plus praziquantel is also used as adjunctive treatment to surgery and percutaneous treatment. Drug treatments have been the indispensable therapeutic modalities for cystic echinococcosis.